Protocol Ledger

NCT03698019 · Phase II · ACTIVE NOT RECRUITING

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Interventional Phase II clinical trial protocol NCT03698019 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-15 Enrollment: 313 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03698019
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)313 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03698019
Protocol FieldVerified Registry Value
NCT IdentifierNCT03698019
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment313 participants (ACTUAL)
Registered Start Date2019-02-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI